Financial reports
10-Q
2020 Q3
Quarterly report
3 Nov 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
6 Mar 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Mar 19
NT 10-K
Notice of late annual filing
18 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
Current reports
8-K
Completion of Acquisition or Disposition of Assets
8 Mar 21
8-K/A
Submission of Matters to a Vote of Security Holders
2 Mar 21
8-K
Material Modifications to Rights of Security Holders
26 Feb 21
8-K
Entry into a Material Definitive Agreement
7 Jan 21
8-K
Other Events
30 Nov 20
8-K
Oxford Immunotec Reports Third Quarter 2020 Financial Results
3 Nov 20
8-K
Oxford Immunotec Reports Second Quarter 2020 Financial Results
4 Aug 20
8-K
Submission of Matters to a Vote of Security Holders
25 Jun 20
8-K
Oxford Immunotec Reports First Quarter 2020 Financial Results
5 May 20
8-K
Oxford Immunotec announces successful re-registration of the T-SPOTĀ®.TB test in China
21 Apr 20
Registration and prospectus
15-12B
Securities registration termination
18 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 21
25-NSE
Exchange delisting
8 Mar 21
424B5
Prospectus supplement for primary offering
16 Aug 17
424B5
Prospectus supplement for primary offering
15 Aug 17
S-3/A
Shelf registration (amended)
23 Jan 17
S-3
Shelf registration
21 Dec 16
424B5
Prospectus supplement for primary offering
30 Jan 15
424B5
Prospectus supplement for primary offering
28 Jan 15
Proxies
DEFM14A
Proxy related to merger
29 Jan 21
PREM14A
Preliminary proxy related to merger
19 Jan 21
DEFA14A
Additional proxy soliciting materials
7 Jan 21
DEFA14A
Additional proxy soliciting materials
1 Jun 20
DEF 14A
Definitive proxy
29 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Jun 19
DEFA14A
Additional proxy soliciting materials
3 May 19
DEF 14A
Definitive proxy
30 Apr 19
PRE 14A
Preliminary proxy
26 Mar 19
DEF 14A
Definitive proxy
27 Apr 18
Other
CT ORDER
Confidential treatment order
31 Dec 20
CT ORDER
Confidential treatment order
31 Dec 20
CT ORDER
Confidential treatment order
31 Dec 20
SEC STAFF
SEC staff action: Order
20 Feb 20
SEC STAFF
SEC staff action: Order
6 Feb 20
CT ORDER
Confidential treatment order
16 May 19
CT ORDER
Confidential treatment order
7 Mar 19
CT ORDER
Confidential treatment order
17 Dec 18
CT ORDER
Confidential treatment order
16 Oct 18
CT ORDER
Confidential treatment order
17 Sep 18
Ownership
SC 13G/A
Alyeska Investment Group, L.P.
14 Feb 22
SC 13G/A
Polar Capital Holdings Plc
14 Feb 22
SC 13G
Grandeur Peak Global Advisors, LLC
7 May 21
4
HERM ROSENMAN
12 Mar 21
4
Matthew T E McLaughlin
12 Mar 21
4
RICHARD A SANDBERG
12 Mar 21
4
Mark R. Klausner
12 Mar 21
4
Janet Louise Kidd
12 Mar 21
4
PATRICIA RANDALL
12 Mar 21
4
PATRICK J BALTHROP
12 Mar 21